Health Canada draft Guidance: Decentralized Clinical Trials
- Sharan Murugan
- 23 minutes ago
- 3 min read
As clinical research continues to evolve, decentralized clinical trials (DCTs) are becoming increasingly important. By incorporating technologies such as telemedicine, remote monitoring, electronic consent, and home healthcare services, decentralized trials can reduce participant burden and improve access to research opportunities.
Recognizing this shift, Health Canada launched a consultation on its Draft Guidance for Decentralized Clinical Trials (DCTs). Feedback from industry, healthcare professionals, researchers, and patient groups was summarized in the "What We Heard" report, which identified five key themes that stakeholders considered essential for the successful implementation of decentralized trials in Canada.
Theme 1: Enhancing Participant-Centric Clinical Research
Stakeholders strongly supported decentralized trial approaches because they can make clinical research more accessible and convenient for participants. Reducing travel requirements and allowing certain trial activities to occur closer to home can help improve recruitment, retention, and overall participant experience.
Respondents also noted that decentralized trials may improve diversity in clinical research by increasing participation among individuals living in rural, remote, or underserved communities. However, stakeholders emphasized that trial designs should remain flexible and accommodate different participant needs and levels of technological literacy.
Theme 2: Defining Roles and Responsibilities
Decentralized clinical trials often involve multiple parties, including sponsors, investigators, contract research organizations, healthcare providers, laboratories, and technology vendors.
Stakeholders highlighted the need for clear accountability and oversight throughout the study. While third parties may perform specific trial activities, responsibilities should be clearly defined and documented to ensure participant protection and regulatory compliance.
Effective communication and coordination among all stakeholders were considered critical for successful trial management.
Theme 3: Protecting Participants Through Consent and Safety Oversight
Participant safety remained one of the most important topics discussed during the consultation.
Stakeholders generally supported electronic informed consent because it can improve accessibility and support remote participation. However, they emphasized that participants should continue to have opportunities to ask questions and fully understand the study before providing consent.
Respondents also stressed the importance of maintaining strong safety monitoring procedures, clear reporting mechanisms, and appropriate medical oversight throughout the trial, regardless of where study activities take place.
Theme 4: Managing Investigational Products
The consultation highlighted the growing use of direct-to-patient shipment of investigational products within decentralized trials.
While stakeholders supported this approach, they emphasized the need to ensure proper storage, transportation, accountability, and product integrity. Clear procedures for product handling and participant education were viewed as essential for maintaining compliance and protecting patient safety.
Sponsors were encouraged to establish robust systems to monitor investigational products throughout distribution and use.
Theme 5: Data Integrity and Digital Technologies
Digital technologies are central to decentralized clinical trials and can improve data collection, participant engagement, and operational efficiency.
Stakeholders emphasized the importance of validated systems, cybersecurity protections, secure data transfer, and reliable monitoring processes. Ensuring data quality and integrity remains essential regardless of where trial activities are conducted.
Respondents also noted that technology access and digital literacy should be considered during trial planning to avoid creating new barriers to participation.
The five themes identified in the consultation—participant-centricity, roles and responsibilities, participant protection, investigational product management, and data integrity—provide an important foundation for the future implementation of decentralized clinical trials in Canada.
Together, these principles support a balanced approach that encourages innovation while maintaining high standards for participant safety and scientific quality.